Sibutramine for obesity
Article Abstract:
Sibutramine hydrochloride monohydrate has been approved by the FDA for treating obesity. The drug, marketed by Knoll as Meridia, is chemically related to amphetamine and has been classified by the Drug Enforcement Agency as a schedule IV controlled substance. In a 24 week trial, 1,024 obese patients on a restricted calorie diet taking a placebo lost 0.9 kg while those taking sibutramine lost between 1.8 and 6.5 kg depending on dosage. The drug seems modestly effective for weight loss, but it increases blood pressure and heart rate and long-term safety is unknown. It is not recommended.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Orlistat for obesity
Article Abstract:
Orlistat is a drug that decreases fat absorption in the gastrointestinal tract. Sold under the trade name Xenical, it inhibits enzymes called lipases, which metabolize fat. It prevents about 30% of dietary fat from being absorbed and this drop in calories is the major cause of weight loss. The drug itself is not absorbed into the bloodstream but is excreted in feces. People may regain some of the weight they lost even if they continue using the drug. It blocks the absorption of some fat-soluble vitamins and can cause intestinal gas and diarrhea.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Dexfenfluramine for obesity
Article Abstract:
Dexfenfluramine (Redux) may be an effective drug treatment for weight loss in conjunction with dietary measures. Its appetite suppressant action may be related to increases in serotonin release. Patients tended to regain the lost weight or report minor discomfort, such as dry mouth, after taking dexfenfluramine. Primary pulmonary hypertension has also been found in the context of taking dexfenfluramine, which may cause serious consequences or death.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Stress management. Stress: a guide for organisations
- Abstracts: Amniotomy in labor - how helpful is it? To stay or not to stay? That is the question. Terra Firma - a journey from migrant farm labor to neurosurgery
- Abstracts: Vitamin E: promising, but don't take its reputation to heart yet. Vitamin D: Individualize your dose
- Abstracts: Pediatric trauma documentation: adequacy for assessment of child abuse. Violence exposure and emotional trauma as contributors to adolescents' violent behaviors
- Abstracts: Dental therapeutic indications for the newer long-acting macrolide antibiotics. Performance of high-speed dental handpieces subjected to simulated clinical use and sterilization